Analogy process for production of optically active or racemic 7-oxo-PG12-derivatives

Optically active or racemic 7-oxo-PGI2-derivatives with the formula:Where Q is hydrogen, a cation or alkyl, X is -CH=CH-, -C=C-, or -CH2CH2-, R is hydrogen, alkanoyl, tetrahydropyran-2-yl or a blocking group with the formula R R R S1 or R -CH2-CR -OR , where R , R , and R are alkyl, R and R are hydrogen or methyl, R is methyl or ethyl, R is hydrogen or a- or -alkyl, R and R are hydrogen or alkyl, Y is methylene, oxygen or -NH-, and R is alkyl, unsubstituted or monosubstituted phenyl or substituted heteroaryl, produced out of compounds with the formula:Upon conversion with a lower alkanol, blocking produced chetals, deacetylization of the protected chetals, oxidation of the blocked chetals, splitting of an alkanol or water, possibly after removal or blocking groups and possibly after acylization of free hydroxy groups, as possible splitting off of still present blocking groups and/or hydrolysis of ester groups and conversion to a salt or an ester.Like the known, naturally occurring PGI2 (prostacyclin), compounds with formula I are effective against circulatory diseases, especially blood clots, but they are much more stable than natural PGI2 in solution, and that is why, even if they have a weaker biological effect than PGI2, they are essentially better as active components in pharmaceutical preparations, as they ensure a homogenous dose without risk for decomposition with consequently weakened activity.